Immunosuppressive Therapy is a treatment used to reduce the activity of the immune system. In this clinical trial, it is used as a standard maintenance therapy for patients with ANCA vasculitis and end-stage renal disease. The goal is to prevent the immune system from attacking the body’s own tissues, which can help manage the symptoms of the disease and prevent further damage to the kidneys.

End-stage Renal Disease – This condition occurs when the kidneys are no longer able to function at a level needed for day-to-day life. It is the final stage of chronic kidney disease, where the kidneys have lost about 90% of their ability to function normally. Patients with this disease often require dialysis or a kidney transplant to survive. The progression involves a gradual decline in kidney function over time, leading to the accumulation of waste products in the body. Symptoms may include fatigue, swelling, and difficulty concentrating. The disease can result from various causes, including diabetes and high blood pressure.

ANCA Vasculitis – This is an autoimmune disease characterized by inflammation of the blood vessels, which can lead to damage in various organs. The condition is associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) in the blood. It can affect small to medium-sized blood vessels, leading to symptoms such as fatigue, fever, and weight loss. As the disease progresses, it can cause organ damage, particularly in the kidneys and lungs. The inflammation can lead to reduced blood flow and tissue damage. The exact cause of ANCA vasculitis is not well understood, but it involves an abnormal immune response.